참고문헌
- Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a metaanalysis. J Natl Cancer Inst 2005;97:188-194 https://doi.org/10.1093/jnci/dji021
- Trop I, LeBlanc SM, David J, Lalonde L, Tran-Thanh D, Labelle M, et al. Molecular classification of infiltrating breast cancer: toward personalized therapy. Radiographics 2014;34:1178-1195 https://doi.org/10.1148/rg.345130049
- Kaufmann M, Von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007;18:1927-1934 https://doi.org/10.1093/annonc/mdm201
- Mathew J, Asgeirsson KS, Cheung KL, Chan S, Dahda A, Robertson JF. Neoadjuvant chemotherapy for locally advanced breast cancer: a review of the literature and future directions. Eur J Surg Oncol 2009;35:113-122 https://doi.org/10.1016/j.ejso.2008.03.015
- Rauch GM, Adrada BE, Kuerer HM, Van la Parra RF, Leung JW, Yang WT. Multimodality imaging for evaluating response to neoadjuvant chemotherapy in breast cancer. AJR Am J Roentgenol 2017;208:290-299 https://doi.org/10.2214/AJR.16.17223
- Chagpar AB, Middleton LP, Sahin AA, Dempsey P, Buzdar AU, Mirza AN, et al. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg 2006;243:257-264 https://doi.org/10.1097/01.sla.0000197714.14318.6f
- Fangberget A, Nilsen LB, Hole KH, Holmen MM, Engebraaten O, Naume B, et al. Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging. Eur Radiol 2011;21:1188-1199 https://doi.org/10.1007/s00330-010-2020-3
- Marinovich ML, Houssami N, Macaskill P, Sardanelli F, Irwig L, Mamounas EP, et al. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. J Natl Cancer Inst 2013;105:321-333 https://doi.org/10.1093/jnci/djs528
- Montemurro F, Martincich L, De Rosa G, Cirillo S, Marra V, Biglia N, et al. Dynamic contrast-enhanced MRI and sonography in patients receiving primary chemotherapy for breast cancer. Eur Radiol 2005;15:1224-1233 https://doi.org/10.1007/s00330-005-2656-6
- McGuire KP, Toro-Burguete J, Dang H, Young J, Soran A, Zuley M, et al. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy? Ann Surg Oncol 2011;18:3149-3154 https://doi.org/10.1245/s10434-011-1912-z
- Bae MS, Shin SU, Ryu HS, Han W, Im SA, Park IA, et al. Pretreatment MR imaging features of triple-negative breast cancer: association with response to neoadjuvant chemotherapy and recurrence-free survival. Radiology 2016;281:392-400 https://doi.org/10.1148/radiol.2016152331
- Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, et al. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol 2001;8:549-559 https://doi.org/10.1007/s10434-001-0549-8
- Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004;10:6622-6628
- Houssami N, Macaskill P, Von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer 2012;48:3342-3354 https://doi.org/10.1016/j.ejca.2012.05.023
- Kawashima H, Inokuchi M, Furukawa H, Ikeda H, Kitamura S. Magnetic resonance imaging features of breast cancer according to intrinsic subtypes: correlations with neoadjuvant chemotherapy effects. Springerplus 2014;3:240
- Ballesio L, Gigli S, Di Pastena F, Giraldi G, Manganaro L, Anastasi E, et al. Magnetic resonance imaging tumor regression shrinkage patterns after neoadjuvant chemotherapy in patients with locally advanced breast cancer: correlation with tumor biological subtypes and pathological response after therapy. Tumour Biol 2017;39:1010428317694540
- Eom HJ, Cha JH, Choi WJ, Chae EY, Shin HJ, Kim HH. Predictive clinicopathologic and dynamic contrast-enhanced MRI findings for tumor response to neoadjuvant chemotherapy in triple-negative breast cancer. AJR Am J Roentgenol 2017;208:W225-W230 https://doi.org/10.2214/AJR.16.17125
- De Los Santos J, Bernreuter W, Keene K, Krontiras H, Carpenter J, Bland K, et al. Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy. Clin Breast Cancer 2011;11:312-319 https://doi.org/10.1016/j.clbc.2011.06.007
- Chen JH, Feig B, Agrawal G, Yu H, Carpenter PM, Mehta RS, et al. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer 2008;112:17-26 https://doi.org/10.1002/cncr.23130
- De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, et al. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. Cancer 2013;119:1776-1783 https://doi.org/10.1002/cncr.27995
- Hayashi Y, Takei H, Nozu S, Tochigi Y, Ichikawa A, Kobayashi N, et al. Analysis of complete response by MRI following neoadjuvant chemotherapy predicts pathological tumor responses differently for molecular subtypes of breast cancer. Oncol Lett 2013;5:83-89 https://doi.org/10.3892/ol.2012.1004
- Ko ES, Han BK, Kim RB, Ko EY, Shin JH, Hahn SY, et al. Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer. Ann Surg Oncol 2013;20:2562-2568 https://doi.org/10.1245/s10434-013-2925-6
- Loo CE, Straver ME, Rodenhuis S, Muller SH, Wesseling J, Vrancken Peeters MJ, et al. Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol 2011;29:660-666 https://doi.org/10.1200/JCO.2010.31.1258
- Kim HJ, Im YH, Han BK, Choi N, Lee J, Kim JH, et al. Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI. Acta Oncol 2007;46:996-1003
- Bouzon A, Acea B, Soler R, Iglesias A, Santiago P, Mosquera J, et al. Diagnostic accuracy of MRI to evaluate tumour response and residual tumour size after neoadjuvant chemotherapy in breast cancer patients. Radiol Oncol 2016;50:73-79 https://doi.org/10.1515/raon-2016-0007
- Akashi-Tanaka S, Fukutomi T, Watanabe T, Katsumata N, Nanasawa T, Matsuo K, et al. Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy. Int J Cancer 2001;96:66-73 https://doi.org/10.1002/1097-0215(20010220)96:1<66::AID-IJC7>3.0.CO;2-T
- Belli P, Costantini M, Malaspina C, Magistrelli A, LaTorre G, Bonomo L. MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy. Clin Radiol 2006;61:946-953 https://doi.org/10.1016/j.crad.2006.07.004
- Rosen EL, Blackwell KL, Baker JA, Soo MS, Bentley RC, Yu D, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am J Roentgenol 2003;181:1275-1282 https://doi.org/10.2214/ajr.181.5.1811275
- Yeh E, Slanetz P, Kopans DB, Rafferty E, Georgian-Smith D, Moy L, et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol 2005;184:868-877 https://doi.org/10.2214/ajr.184.3.01840868
- Bahri S, Chen JH, Mehta RS, Carpenter PM, Nie K, Kwon SY, et al. Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. Ann Surg Oncol 2009;16:1619-1628 https://doi.org/10.1245/s10434-009-0441-5
- Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol 2002;179:1193-1199 https://doi.org/10.2214/ajr.179.5.1791193
- Jeon YW, Kim TH, Youn HJ, Han S, Jung Y, Gwak G, et al. Multicenter phase II trial of neoadjuvant chemotherapy with docetaxel and gemcitabine in locally advanced breast cancer. J Breast Cancer 2017;20:340-346 https://doi.org/10.4048/jbc.2017.20.4.340
- Schrading S, Kuhl CK. Breast cancer: influence of taxanes on response assessment with dynamic contrast-enhanced MR imaging. Radiology 2015;277:687-696 https://doi.org/10.1148/radiol.2015150006